Sapio’s Acquisition of Homeperf

Goodwin Procter LLP advised the French private equity firm Parquest Capital in the transaction, while Nctm Studio Legale and Gide Loyrette Nouel advised Sapio.

Parquest Capital announced the sale of Homeperf, a French leading homecare service provider specialized in perfusion, nutrition, insulin therapy and respiratory assistance services, to Italian leading company in homecare and in the manufacture of industrial technical and medical gases, Sapio.

Homeperf was established in 1997 and is now a consolidated presence nationwide, with 37 agencies and around 360 employees, headquartered in Aix-en-Provence. The company operates in homecare and specializes in assisting patients by providing solutions for artificial nutrition, perfusion, insulin and respiratory therapy. In 2019 Homeperf’s turnover was €52 million.

The Sapio Group, founded in 1922 with headquarters in Monza, operates in the industrial and medical gas sector and in homecare all over Italy, and in France, Germany, Slovenia, Turkey and Spain.

With a turnover of €550 million and 1800 employees, it produces, develops and markets gases, innovative technologies and integrated services for the industrial sector. In addition to producing and supplying medical gases for hospitals and social and health facilities, it also offers medical devices, integrated home care and palliative care.

The Goodwin team was led by partner Thomas Maitrejean (picture) and included Edouard Baladès, Jérémie Ruiz, Adrien Paturaud and Marie-Laure Bruneel.

Nctm Studio Legale advised Sapio on the acquisition with a team composed by Michele Motta and Mario Bonferroni.

Involved fees earner: Édouard Baladès – Goodwin Procter; Marie-Laure Bruneel – Goodwin Procter; Thomas Maitrejean – Goodwin Procter; Adrien Paturaud – Goodwin Procter; Jérémie Ruiz – Goodwin Procter; Mario Bonferroni – NCTM; Michele Motta – NCTM;

Law Firms: Goodwin Procter; NCTM;

Clients: Parquest Capital; Sapio Group;